v3.26.1
Revenue - Schedule of Product Sales (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue Recognition    
Total revenue $ 139,514 $ 666,655
Product sales    
Revenue Recognition    
Total revenue 42,200 621,678
Nuvaxovid sales    
Revenue Recognition    
Total revenue 9,558 608,025
Supply sales    
Revenue Recognition    
Total revenue $ 32,642 $ 13,653